NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women | NIH: National Institute of Allergy and Infectious Diseases

NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women | NIH: National Institute of Allergy and Infectious Diseases

NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women

          The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa. The NIH-funded study also will test the safety of a daily oral antiviral tablet for HIV pre-exposure prophylaxis (PrEP) in pregnant women and will assess how much they accept and use these two HIV prevention tools. The study will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first six months after birth.  

          “Women need reliable HIV prevention methods that they know are safe during pregnancy for themselves and their babies,” said NIAID Director Anthony S. Fauci, M.D. “This new clinical trial will provide important data on the safety of PrEP and the dapivirine ring during pregnancy and will help expectant parents make well-informed HIV prevention choices.”

          Read the NIAID press release.